Eisai

News

Appeal finds NICE must reconsider Alzheimer's drugs

Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.

News

Eisai joins with Pokémon for sleep awareness drive

Eisai has launched a campaign to raise awareness of sleep disorders in Japan, via a partnership with smartphone app Pokémon Sleep.

News

Eisai unveils digital platform for kidney cancer patients

Eisai has launched a 'digital destination', called Kompass, that aims to support patients after they have been given a diagnosis of kidney cancer.

News

Man yawning, covering his mouth with his hand

FDA kicks off review of Takeda's narcolepsy hopeful

The FDA has started a priority review of Takeda's oveporexton for sleep disorder narcolepsy, setting up a decision in the third quarter of the year.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

Eisai settles Lenvima patent dispute with Torrent Pharma

A settlement between Eisai and Torrent Pharma will keep a generic version of blockbuster cancer drug Lenvima off the US market until 2030.

Appeal finds NICE must reconsider Alzheimer's drugs

Eisai joins with Pokémon for sleep awareness drive

Eisai unveils digital platform for kidney cancer patients

FDA kicks off review of Takeda's narcolepsy hopeful

CMS's Medicare price negotiations start round three

Eisai settles Lenvima patent dispute with Torrent Pharma

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Eisai

Editor's Picks